CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus ...

Large cell carcinoma is aggressive, requiring early detection through imaging and biopsy for optimal treatment outcomes.

Dual Versus Single Checkpoint Inhibition in Advanced Non-Small Cell Lung Cancer: A Pooled Patient-Level Analysis of Six ...

The company said that responding patients lived longer overall, with a median survival of 16.2 months. ・The data come from ...

Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...

UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the ...

The early-stage clinical trial marks the first U.S. testing of Alveltamig, an immunotherapy designed to help the immune system better recognize and respond to small cell lung cancer. The study aims to ...

While the statistics remain stark—lung cancer is the most common type of cancer worldwide and has the highest death ...

LEXINGTON The University of Kentucky Markey Cancer Center has treated the first patient in the U.S. with a new immunotherapy ...

In a cohort study of patients with advanced non-small cell lung cancer (NSCLC), exposure to certain antibiotics, high-dose steroids, or proton pump inhibitors (PPIs) at the start of immunotherapy was ...

Scientists, medical researchers at Case Western Reserve, NYU Langone Health and University Hospitals using machine-learning to predict response to immunotherapy Medical researchers from Case Western ...

A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor ...